Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1267
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 325–336 of 1,267 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational

Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome

NCT05344599
Site status not listed — check the official record
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Acute Hepatic Porphyria
Interventions
Autonomic Function Testing, Genetic Testing, Urine Testing, Blood laboratory Testing
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Corticosteroid for Diabetic Macular Edema (DME) Study

NCT07843849
Status at this site: Recruiting
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Diabetic Retinopathy
Interventions
Intravitreal dexamethasone implant
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
90
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Recruiting Phase 2Phase 3 Interventional

Nectero EAST System Clinical Study

NCT06001918
Status at this site: Recruiting
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Nectero EAST System
Drug
Lead sponsor
Nectero Medical, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
40
States / cities
Scottsdale, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
109
States / cities
Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Recruiting Phase 2 Interventional

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

NCT06075953
Status at this site: Recruiting
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
29
States / cities
Berkeley, California • Duarte, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Recruiting Not applicable Interventional

A Prospective Analysis of Long-Term Clinical Outcomes and 3D Spine Growth in Anterior Vertebral Body Tethering

NCT04914507
Status at this site: Recruiting
View directory record Official record
Conditions
Scoliosis Idiopathic
Interventions
Anterior Vertebral Body Tethering
Device
Lead sponsor
Pediatric Spine Foundation
Other
Eligibility
Up to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Saint Paul, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445
Site status not listed — check the official record
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
52
States / cities
Lancaster, California • Los Angeles, California • Colorado Springs, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059
Site status not listed — check the official record
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Recruiting Phase 2 Interventional

Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation

NCT07549503
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Liver Transplant
Interventions
Immunosuppression Reduction
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 13 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Recruiting Phase 2 Interventional

Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels

NCT05766839
Status at this site: Recruiting
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
0 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 6:48 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 6:48 AM EDT

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.